CD40LG and breast carcinoma: While our data identify CD40L as one of the most potent stimulus to condition blood DC from patients with breast cancer, studies on the combined use of TLR ligands with pro-inflammatory cytokines demonstrate that combinatorial stimulation provide strong IL-12 secretion in vitro and thus may provide a better biological framework on which to develop effective DC-based immunotherapies for breast cancer.